Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset
Type 1 Diabetes TrialNet Canakinumab Study Group (Lise Tarnow, members) , The AIDA Study Group (Flemming Pociot, members), Flemming Pociot (Medlem af forfattergruppering), Jørgen Rungby (Medlem af forfattergruppering)
Dyk ned i forskningsemnerne om 'Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset'. Sammen danner de et unikt fingeraftryk.